Drugs in early clinical development for the treatment of osteosarcoma

References

• Mirabello L, Troisi RJ, Savage SA. International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons. Int J Cancer. 2009;125:229–234.
   PubMed Web of Science ®Google Scholar
• Hauben EI, Hogendoorn PCW. Epidemiology of primary bone tumors and economial aspects of bone metastases. In: Heymann D, editor. Bone cancer. San Diego: Academic Press; 2015. p. 5–9.
   Google Scholar
• Inwards C, Suire J. Low-grade central osteosarcoma. In: IARC, editor. WHO classification of tumours of soft tissue and bone. Lyon (France): IARC press; 2013. p. 281–282.
   Google Scholar
• Rosenberg AE, Cleton-Jansen AM, de Pinieux G, et al. In: IARC, editor. WHO classification of tumours of soft tissue and bone. Lyon (France): IARC press; 2013. p. 282–288.
   Google Scholar
• Oliveira AM, Okada K, Suire J. Telangiectatic osteosarcoma. In: IARC, editor. WHO classification of tumours of soft tissue and bone. Lyon (France): IARC press; 2013. p. 289–290.
   Google Scholar
• Kalil RK, Suire J. Small cell osteosarcoma. In: IARC, editor. WHO classification of tumours of soft tissue and bone. Lyon (France): IARC press; 2013. p. 291.
   Google Scholar
• Lazar A, Mertens F. Parosteal osteosarcoma. In: IARC, editor. WHO classification of tumours of soft tissue and bone. Lyon (France): IARC press; 2013. p. 92–293.
   Google Scholar
• Montag AG, Suire J. Periosteal osteosarcoma. In: IARC, editor. WHO classification of tumours of soft tissue and bone. Lyon (France): IARC press; 2013. p. 294.
   Google Scholar
• Wold LE, McCarthy EF, Squire J. High-grade surface osteosarcoma. In: IARC, editor. WHO classification of tumours of soft tissue and bone. Lyon (France): IARC press; 2013. p. 295–296.
   Google Scholar
• Heymann D, Redini F. Bone sarcomas: pathogenesis and new therapeutic approaches. IBMS BoneKEy. 2011;8:402–414.
   Google Scholar
• Mohseny AB, Hogendoorn PC. Concise review: mesenchymal tumors: when stem cells go mad. Stem Cells. 2011;29:397–403.
   PubMed Web of Science ®Google Scholar
• Mutsaers AJ, Walkley CR. Cells of origin in osteosarcoma: mesenchymal stem cells or osteoblast committed cells? Bone. 2014;62:56–63.
   PubMed Web of Science ®Google Scholar
• Bousquet M, Noirot C, Accadbled F, et al. Whole-exome sequencing in osteosarcoma reveals important heterogeneity of genetic alterations. Ann Oncol. 2016;27:738–744.
   PubMed Web of Science ®Google Scholar
• Kovac M, Blattmann C, Ribi S, et al. Exome sequencing of osteosarcoma reveals mutation signatures reminiscent of BRCA deficiency. Nat Commun. 2015;6:8940.
   PubMed Web of Science ®Google Scholar
• Walkley CR, Qudsi R, Sankaran VG, et al. Conditional mouse osteosarcoma, dependent on p53 loss and potentiated by loss of Rb, mimics the human disease. Genes Dev. 2008;22:1662–1676.
   PubMed Web of Science ®Google Scholar
• Lin PP, Pandey MK, Jin F, et al. Targeted mutation of p53 and Rb in mesenchymal cells of the limb bud produces sarcomas in mice. Carcinogenesis. 2009;30:1789–1795.
   PubMed Web of Science ®Google Scholar
• Berman SD, Calo E, Landman AS, et al. Metastatic osteosarcoma induced by inactivation of Rb and p53 in the osteoblast lineage. Proc Natl Acad Sci USA. 2008;105:11851–11856.
   PubMed Web of Science ®Google Scholar
• Mutsaers AJ, Ng AJ, Baker EK, et al. Modeling distinct osteosarcoma subtypes in vivo using cre: loxand lineage-restricted transgenic shRNA. Bone. 2013;55:166–178.
   PubMed Web of Science ®Google Scholar
• Wittrant Y, Théoleyre S, Chipoy C, et al. RANKL/RANK/OPG: new therapeutic targets in bone tumours and associated osteolysis. Biochim Biophys Acta. 2004;1704:49–57.
   PubMed Web of Science ®Google Scholar
• Borovski T, De Sousa E Melo F, Vermeulen L, et al. Cancer stem cell niche: the place to be. Cancer Res. 2011;71:634–639.
   PubMed Web of Science ®Google Scholar
• Perrot P, Rousseau J, Bouffaut AL, et al. Safety concern between autologous fat graft, mesenchymal stem cell and osteosarcoma recurrence. PLoS One. 2010;5:e10999.
   Google Scholar
• Avril P, Duteille F, Ridel P, et al. Opposite effects of soluble factors secreted by adipose tissue on proliferating and quiescent osteosarcoma cells. Plast Reconstr Surg. 2016;137:865–875.
   PubMed Web of Science ®Google Scholar
• Clark JC, Dass CR, Choong PF. A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol. 2008;134:281–297.
   PubMed Web of Science ®Google Scholar
• Allison DC, Caarney SC, Ahlmann ER, et al. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma. 2012;2012:704872.
   PubMedGoogle Scholar
• Mirabello L, Troisi RJ, Savage SA. Osteosarcoma incidence and survival rates from 1973 to 2004: data from the surveillance, epidemiology, and end results program. Cancer. 2009;115:1531–1543.
   PubMed Web of Science ®Google Scholar
• Rosen G, Tan C, Sanmaneechai A, et al. The rationale for multiple drug chemotherapy in the treatment of osteogenic sarcoma. Cancer. 1975;35:936–945.
   PubMed Web of Science ®Google Scholar
• Link MP, Goorin AM, Miser AW, et al. The effect of adjuvant chemotherapy on relapse-free survival in patients with osteosarcoma of the extremity. N Engl J Med. 1986;314:1600–1606.
   PubMed Web of Science ®Google Scholar
• Bacci G, Longhi A, Fagioli F, et al. Adjuvant and neoadjuvant chemotherapy for osteosarcoma of the extremities: 27 year experience at Rizzoli Institute, Italy. Eur J Cancer. 2005;41:2836–2845.
   PubMed Web of Science ®Google Scholar
• Whelan JS, Jinks RC, McTiernan A, et al. Survival from high-grade localised extremity osteosarcoma: combined results and prognostic factors from three European Osteosarcoma Intergroup randomised controlled trials. Ann Oncol. 2012;23:1607–1616.
   PubMed Web of Science ®Google Scholar
• McTiernan A, Jinks RC, Sydes MR, et al. Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup. Eur J Cancer. 2012;48:703–712.
   PubMed Web of Science ®Google Scholar
• Goorin AM, Schwartzentruber DJ, Devidas M, et al. Presurgical chemotherapy compared with immediate surgery and adjuvant chemotherapy for nonmetastatic osteosarcoma: Pediatric Oncology Group Study POG-8651. J Clin Oncol. 2003;21:1574–1580.
   PubMed Web of Science ®Google Scholar
• Carrle D, Bielack SS. Current strategies of chemotherapy in osteosarcoma. Int Orthop. 2006; 30:445–451.
   PubMed Web of Science ®Google Scholar
• Huvos A. Osteogenic osteosarcoma. In: Huvos A, editor. Bone tumors: diagnosis, treatment and prognosis. 2nd ed. Philadelphia: WB Saunders; 1991. p. 85–156.
   Google Scholar
• Gouin F, Heymann MF. Margins and bone tumors – what are we talking about? In: Heymann D, editor. Bone cancer. San Diego: Academic Press; 2015. p. 287–291.
   Google Scholar
• Bertrand TE, Cruz A, Binitie O, et al. Do surgical margins affect local recurrence and survival in extremity, nonmetastatic, high-grade osteosarcoma? Clin Orthop Relat Res. 2016;474:677–683.
   PubMed Web of Science ®Google Scholar
• Bielack S, Kempf-Bielack B, Von Kalle T, et al. Controversies in childhood osteosarcoma. Minerva Pediatr. 2013;65:125–148.
   PubMed Web of Science ®Google Scholar
• Whelan JS, Bielack SS, Marina N, et al. EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment. Ann Oncol. 2015;26:407–414.
   PubMed Web of Science ®Google Scholar
• Marina N, Smeland S, Bielack SS, et al. MAPIE vs MAP as postoperative chemotherapy in patients with a poor response to preoperative chemotherapy for newly-diagnosed osteosarcoma: results from EURAMOS-1. Connective Tissue Oncology Society (CTOS). 2014; paper 032 October 2014, Berlin, Germany.
   Google Scholar
• Bielack SS, Smeland S, Whelan JS, et al. Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon Alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: first results of the EURAMOS-1 good response randomized controlled trial. J Clin Oncol. 2015;33:2279–2287.
   PubMed Web of Science ®Google Scholar
• Schwarz R, Bruland O, Cassoni A, et al. The role of radiotherapy in oseosarcoma. Cancer Treat Res. 2009;152:147–164.
   PubMedGoogle Scholar
• Ozaki T, Flege S, Kevric M, et al. Osteosarcoma of the pelvis: experience of the Cooperative Osteosarcoma Study Group. J Clin Oncol. 2003;21:334–341.
   PubMed Web of Science ®Google Scholar
• DeLaney TF, Park L, Goldberg SI, et al. Radiotherapy for local control of osteosarcoma. Int J Radiat Oncol Biol Phys. 2005;61:492–498.
   PubMed Web of Science ®Google Scholar
• Errani C, Longhi A, Rossi G, et al. Palliative therapy for osteosarcoma. Expert Rev Anticancer Ther. 2011;11:217–227.
   PubMed Web of Science ®Google Scholar
• Rahn DA 3rd, Mundt AJ, Murphy JD, et al. Clinical outcomes of palliative radiation therapy for children. Pract Radiat Oncol. 2015;5:183–187.
   PubMedGoogle Scholar
• Heymann D, Redini F. Targeted therapies for bone sarcomas. BoneKey Rep. 2013;2:378.
   PubMedGoogle Scholar
• Ando K, Heymann MF, Stresing V, et al. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers. 2013;5:591–616.
   PubMedGoogle Scholar
• Hattinger CM, Fanelli M, Tavani E, et al. Advances in emerging drugs for osteosarcoma. Expert Opin Emerg Drugs. 2015;20:495–514.
   PubMed Web of Science ®Google Scholar
• Burrow S, Andrulis IL, Pollak M, et al. Expression of insulin-like growth factor receptor, IGF-1, and IGF-2 in primary and metastatic osteosarcoma. J Surg Oncol. 1998;69:21–27.
   PubMed Web of Science ®Google Scholar
• Jentzsch T, Robl B, Husmann M, et al. Worse prognosis of osteosarcoma patients expressing IGF-1 on a tissue microarray. Anticancer Res. 2014;34:3881–3889.
   PubMed Web of Science ®Google Scholar
• Schwartz GK, Tap WD, Qin LX, et al. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol. 2013;14:371–382.
   PubMed Web of Science ®Google Scholar
• Bagatell R, Herzog CE, Trippett TM, et al. Pharmacokinetically guided phase 1 trial of the IGF-1 receptor antagonist RG1507 in children with recurrent or refractory solid tumors. Clin Cancer Res. 2011;17:611–619.
   PubMed Web of Science ®Google Scholar
• Avnet S, Sciacca L, Salerno M, et al. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma. Cancer Res. 2009;69:2443–2452.
   PubMed Web of Science ®Google Scholar
• Wan X, Harkavy B, Shen N, et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene. 2006;26:1932–1940.
   PubMed Web of Science ®Google Scholar
• Penel-Page M, Ray-Coquard I, Larcade J, et al. Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes). BMC Cancer. 2015;15:854.
   PubMed Web of Science ®Google Scholar
• Ségaliny AI, Tellez-Gabriel M, Heymann MF, et al. Receptor tyrosine kinases: characterisation, mechanism of action and therapeutic interests for bone cancers. J Bone Oncol. 2015;4:1–12.
   PubMed Web of Science ®Google Scholar
• Chugh R, Wathen JK, Maki RG, et al. Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model. J Clin Oncol. 2009;27:3148–3153.
   PubMed Web of Science ®Google Scholar
• Bond M, Bernstein ML, Pappo A, et al. A phase II study of imatinib mesylate in children with refractory or relapsed solid tumours: a Children’s Oncology Group study. Pediatr Blood Cancer. 2008;50:254–258.
   PubMed Web of Science ®Google Scholar
• Aplenc R, Blaney SM, Strauss LC, et al. Pediatric phase I trial and pharmacokinetic study of dasatinib: a report from the Children’s Oncology Group phase I consortium. J Clin Oncol. 2011;29:839–844.
   PubMed Web of Science ®Google Scholar
• Maris JM, Courtright J, Houghton PJ, et al. Initial testing (stage 1) of sunitinib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;51:42–48.
   PubMed Web of Science ®Google Scholar
• Dubois SG, Shusterman S, Ingle AM, et al. Phase I and pharmacokinetic study of sunitinib in pediatric patients with refractory solid tumours: a Children’s Oncology Group study. Clin Cancer Res. 2011;17:5113–5122.
   PubMed Web of Science ®Google Scholar
• Keir ST, Morton CL, Wu J, et al. Initial testing of the multitargeted kinase inhibitor pazopanib by the pediatric preclinical testing program. Pediatr Blood Cancer. 2012;59:586–588.
   PubMed Web of Science ®Google Scholar
• Safwat A, Boysen A, Lücke A, et al. Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients. Acta Oncol. 2014;53:1451–1454.
   PubMed Web of Science ®Google Scholar
• Navid F, Baker SD, McCarville MB, et al. Phase I and clinical pharmacology study of bevacizumab, sorafenib, and low-dose cyclophosphamide in children and young adults with refractory/recurrent solid tumors. Clin Cancer Res. 2013;19:236–246.
   PubMed Web of Science ®Google Scholar
• Grignani G, Palmerini E, Dileo P, et al. A phase II trial of sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of standard multimodal therapy: an Italian Sarcoma Group study. Ann Oncol. 2012;23:508–516.
   PubMed Web of Science ®Google Scholar
• Grignani G, Palmerini E, Ferraresi V, et al. Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16:98–107.
   PubMed Web of Science ®Google Scholar
• Mross K, Frost A, Steinbild S, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;8:2658–2667.
   Web of Science ®Google Scholar
• Cooper CS, Park M, Blair DG, et al. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature. 1984;311:29–33.
   PubMed Web of Science ®Google Scholar
• Scotlandi K, Baldini N, Oliviero M, et al. Expression of Met/hepatocyte growth factor receptor gene and malignant behavior of musculoskeletal tumors. Am J Pathol. 1996;149:1209–1219.
   PubMed Web of Science ®Google Scholar
• Ferracini R, Angelini P, Cagliero E, et al. MET oncogene aberrant expression in canine osteosarcoma. J Orthop Res. 2000;18:253–256.
   PubMed Web of Science ®Google Scholar
• Oda Y, Naka T, Takeshita M, et al. Comparison of histological changes and changes in nm23 and c-MET expression between primary and metastatic sites in osteosarcoma: a clinicopathologic and immunohistochemical study. Hum Pathol. 2000;31:709–716.
   PubMed Web of Science ®Google Scholar
• Sampson ER, Martin BA, Morris AE, et al. The orally bioavailable met inhibitor PF-2341066 inhibits osteosarcoma growth and osteolysis/matrix production in a xenograft model. J Bone Miner Res. 2011;26:1283–1294.
   PubMed Web of Science ®Google Scholar
• Wang K, Zhuang Y, Liu C, et al. Inhibition of c-Met activation sensitizes osteosarcoma cells to cisplatin via suppression of the PI3K-Akt signaling. Arch Biochem Biophys. 2012;526:38–43.
   PubMed Web of Science ®Google Scholar
• Heymann D, Ory B, Gouin F, et al. Bisphosphonates: new therapeutic agents for the treatment of bone tumors. Trends Mol Med. 2004;10:337–343.
   PubMed Web of Science ®Google Scholar
• Moriceau G, Ory B, Gobin B, et al. Therapeutic approach of primary bone tumours by bisphosphonates. Curr Pharm Des. 2010;16:2981–2987.
   PubMed Web of Science ®Google Scholar
• Ory B, Blanchard F, Battaglia S, et al. Zoledronic acid activates the DNA S-phase checkpoint and induces osteosarcoma cell death characterized by apoptosis-inducing factor and endonuclease-G translocation independently of p53 and retinoblastoma status. Mol Pharmacol. 2007;71:333–343.
   PubMed Web of Science ®Google Scholar
• Muraro M, Mereuta OM, Carraro F, et al. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. Cell Immunol. 2007;249:63–72.
   PubMed Web of Science ®Google Scholar
• Heymann D, Ory B, Blanchard F, et al. Enhanced tumor regression and tissue repair when zoledronic acid is combined with ifosfamide in rat osteosarcoma. Bone. 2005;37:74–86.
   PubMed Web of Science ®Google Scholar
• Dass CR, Choong PF. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol Cancer Ther. 2007;6:3263–3270.
   PubMed Web of Science ®Google Scholar
• Ory B, Heymann MF, Kamijo A, et al. Zoledronic acid suppresses lung metastases and prolongs overall survival of osteosarcoma-bearing mice. Cancer. 2005;104:2522–2529.
   PubMed Web of Science ®Google Scholar
• Koto K, Horie N, Kimura S, et al. Clinically relevant dose of zoledronic acid inhibits spontaneous lung metastasis in a murine osteosarcoma model. Cancer Lett. 2009;274:271–278.
   PubMed Web of Science ®Google Scholar
• Benassi MS, Chiechi A, Ponticelli F, et al. Growth inhibition and sensitization to cisplatin by zoledronic acid in osteosarcoma cells. Cancer Lett. 2007;250:194–205.
   PubMed Web of Science ®Google Scholar
• Ohba T, Cates JM, Cole HA, et al. Pleiotropic effects of bisphosphonates on osteosarcoma. Bone. 2014;63:110–120.
   Google Scholar
• Endo-Munoz L, Cumming A, Rickwood D, et al. Loss of osteoclasts contributes to development of osteosarcoma pulmonary metastases. Cancer Res. 2010;70:7063–7072.
   PubMed Web of Science ®Google Scholar
• Piperno-Neumann S, Le Deley M, Rédini F, et al. Zoledronate does not reduce the risk of treatment failure in osteosarcoma: results of the French multicentre OS2006 randomised trial. Ann Oncol. 2014;25(suppl_4):iv494–iv510.
   Google Scholar
• Ory B, Moriceau G, Trichet V, et al. Farnesyl diphosphate synthase is involved in the resistance to zoledronic acid of osteosarcoma cells. J Cell Mol Med. 2008;12:928–994.
   PubMed Web of Science ®Google Scholar
• Yoshiyama A, Morii T, Ohtsuka K, et al. Development of stemness in cancer cell lines resistant to the anticancer effects of zoledronic acid. Anticancer Res. 2016;36:625–631.
   PubMed Web of Science ®Google Scholar
• Dieli F, Gebbia N, Poccia F, et al. Induction of gammadelta T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood. 2003;102(6):2310–2311.
   PubMed Web of Science ®Google Scholar
• Li Z, Peng H, Xu Q, et al. Sensitization of human osteosarcoma cells to Vγ9Vδ2 T-cell-mediated cytotoxicity by zoledronate. J Orthop Res. 2012;30(5):824–830.
   PubMed Web of Science ®Google Scholar
• Theoleyre S, Wittrant Y, Kwan Tat SK, et al. The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling. Cytokine Growth Factor Rev. 2004;15:457–475.
   PubMed Web of Science ®Google Scholar
• Mori K, Le Goff B, Berreur M, et al. Human osteosarcoma cells express functional receptor activator of nuclear facto-kappa B. J Pathol. 2007;211:555–562.
   PubMed Web of Science ®Google Scholar
• Trieb K, Windhager R. Receptor activator of nuclear factor κB expression is a prognostic factor in human osteosarcoma. Oncol Lett. 2015;10:1813–1815.
   PubMed Web of Science ®Google Scholar
• Bago-Horvath Z, Schmid K, Rössler F, et al. Impact of RANK signalling on survival and chemotherapy response in osteosarcoma. Pathology. 2014;46:411–415.
   PubMed Web of Science ®Google Scholar
• Lee JA, Jung JS, Kim DH, et al. RANKL expression is related to treatment outcome of patients with localized, high-grade osteosarcoma. Pediatr Blood Cancer. 2011;56:738–743.
   PubMed Web of Science ®Google Scholar
• Branstetter D, Rohrbach K, Huang LY, et al. RANK and RANK ligand expression in primary human osteosarcoma. J Bone Oncol. 2014;4:59–68.
   Web of Science ®Google Scholar
• Lamoureux F, Picarda G, Rousseau J, et al. Therapeutic efficacy of soluble receptor activator of nuclear factor-kappa B-Fc delivered by nonviral gene transfer in a mouse model of osteolytic osteosarcoma. Mol Cancer Ther. 2008;7:3389–3398.
   PubMed Web of Science ®Google Scholar
• Qiao B, Shui W, Cai L, et al. Human mesenchymal stem cells as delivery of osteoprotegerin gene: homing and therapeutic effect for osteosarcoma. Drug Des Devel Ther. 2015;9:969–976.
   PubMed Web of Science ®Google Scholar
• Chen Y, Di Grappa MA, Molyneux SD, et al. RANKL blockade prevents and treats aggressive osteosarcomas. Sci Transl Med. 2015;7:317ra197.
   PubMed Web of Science ®Google Scholar
• Tan W, Zhang W, Strasner A, et al. Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature. 2011;470:548–553.
   PubMed Web of Science ®Google Scholar
• Gobin B, Baud’huin M, Isidor B, et al. Monoclonal antibodies targeting RANKL in bone metastasis treatment. In: Fatih M, editor. Monoclonal antibodies in oncology. Uckum: eBook Future Medicine Ltd; 2012. p. 42–53.
   Google Scholar
• Cathomas R, Rothermundt C, Bode B, et al. RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward? Oncology. 2015;88:257–260.
   PubMed Web of Science ®Google Scholar
• DeRenzo C, Gottschalk S. Genetically modified T-cell therapy for osteosarcoma. Adv Exp Med Biol. 2014;804:323–340.
   PubMed Web of Science ®Google Scholar
• Li Z. Potential of human γδ T cells for immunotherapy of osteosarcoma. Mol Biol Rep. 2013;40:427–437.
   PubMed Web of Science ®Google Scholar
• Tarek N, Lee DA. Natural killer cells for osteosarcoma. Adv Exp Med Biol. 2014;804:341–353.
   PubMed Web of Science ®Google Scholar
• Endo-Munoz L, Evdokiou A, Saunders NA. The role of osteoclasts and tumour-associated macrophages in osteosarcoma metastasis. Biochim Biophys Acta. 2012;1826:434–442.
   PubMed Web of Science ®Google Scholar
• Kurzman ID, Shi F, Vail DM, et al. In vitro and in vivo enhancement of canine pulmonary alveolar macrophage cytotoxic activity against canine osteosarcoma cells. Cancer Biother Radiopharm. 1999;14:121–128.
   PubMed Web of Science ®Google Scholar
• Kurzman ID, MacEwen EG, Rosenthal RC, et al. Adjuvant therapy for osteosarcoma in dogs: results of randomized clinical trials using combined liposome-encapsulated muramyl tripeptide and cisplatin. Clin Cancer Res. 1995;1:1595–1601.
   PubMed Web of Science ®Google Scholar
• MacEwen EG, Kurzman ID, Helfand S, et al. Current studies of liposome muramyl tripeptide (CGP 19835A lipid) therapy for metastasis in spontaneous tumors: a progress review. J Drug Target. 1994;2:391–396.
   PubMed Web of Science ®Google Scholar
• Kurzman ID, Cheng H, MacEwen EG. Effect of liposome-muramyl tripeptide combined with recombinant canine granulocyte colony-stimulating factor on canine monocyte activity. Cancer Biother. 1994;9:113–121.
   PubMedGoogle Scholar
• Smith BW, Kurzman ID, Schultz KT, et al. Muramyl peptides augment the in vitro and in vivo cytostatic activity of canine plastic-adherent mononuclear cells against canine osteosarcoma cells. Cancer Biother. 1993;8:137–144.
   PubMedGoogle Scholar
• MacEwen EG, Kurzman ID, Rosenthal RC, et al. Therapy for osteosarcoma in dogs with intravenous injection of liposome-encapsulated muramyl tripeptide. J Natl Cancer Inst. 1989;81:935–938.
   PubMed Web of Science ®Google Scholar
• MacEwen EG. An immunologic approach to the treatment of cancer. Vet Clin North Am. 1977;7:65–75.
   PubMedGoogle Scholar
• Mori K, Ando K, Heymann D. Liposomal muramyl tripeptide phosphatidyl ethanolamine: a safe and effective agent against osteosarcoma pulmonary metastases. Expert Rev Anticancer Ther. 2008;8:151–159.
   PubMed Web of Science ®Google Scholar
• Ando K, Mori K, Corradini N, et al. Mifamurtide for the treatment of nonmetastatic osteosarcoma. Expert Opin Pharmacother. 2011;12:285–292.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo MD, et al. Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival – a report from the Children’s Oncology Group. J Clin Oncol. 2008;26:633–638.
   PubMed Web of Science ®Google Scholar
• Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol. 2005;23(9):2004–2011.
   PubMed Web of Science ®Google Scholar
• Mifamurtide: osteosarcoma: ineffective and harmful. Prescrire Int. 2011;20:89.
   PubMedGoogle Scholar
• Kager L, Pötschger U, Bielack S. Review of mifamurtide in the treatment of patients with osteosarcoma. Ther Clin Risk Manag. 2010;6:279–286.
   PubMed Web of Science ®Google Scholar
• Cook J, Hagemann T. Tumour-associated macrophages and cancer. Curr Opin Pharmacol. 2013;13:595–601.
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Raymond AK, Bucana CD, et al. Unique histological changes in lung metastases of osteosarcoma patients following therapy with liposomal muramyl tripeptide (CGP 19835A lipid). Cancer Immunol Immunother. 1992;34:211–220.
   PubMed Web of Science ®Google Scholar
• Kleinerman ES, Gano JB, Johnston DA, et al. Efficacy of liposomal muramyl tripeptide (CGP 19835A) in the treatment of relapsed osteosarcoma. Am J Clin Oncol. 1995;18:93–99.
   PubMed Web of Science ®Google Scholar
• Buddingh EP1, Kuijjer ML, Duim RA, et al. Tumor-infiltrating macrophages are associated with metastasis suppression in high-grade osteosarcoma: a rationale for treatment with macrophage activating agents. Clin Cancer Res. 2011;17:2110–2119.
   PubMed Web of Science ®Google Scholar
• Ségaliny AI, Mohamadi A, Dizier B, et al. Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer. 2015;137:73–85.
   PubMed Web of Science ®Google Scholar
• Chou AJ, Kleinerman ES, Krailo MD, et al. Addition of muramyl tripeptide to chemotherapy for patients with newly diagnosed metastatic osteosarcoma: a report from the Children’s Oncology Group. Cancer. 2009;115:5339–5348.
   PubMed Web of Science ®Google Scholar
• Barouch-Bentov R, Sauer K. Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs. 2011;20:153–208.
   PubMed Web of Science ®Google Scholar
• Serra M, Pasello M, Manara MC, et al. May P-glycoprotein status be used to stratify high-grade osteosarcoma patients? Results from the Italian/Scandinavian Sarcoma Group 1 treatment protocol. Int J Oncol. 2006;29:1459–1468.
   PubMed Web of Science ®Google Scholar
• Pahl JH, Kwappenberg KM, Varypataki EM, et al. Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ. J Exp Clin Cancer Res. 2014;33:27.
   PubMed Web of Science ®Google Scholar
• Heiner JP, Miraldi F, Kallick S, et al. Localization of GD2-specific monoclonal antibody 3F8 in human osteosarcoma. Cancer Res. 1987;47:5377–5381.
   PubMed Web of Science ®Google Scholar
• Yu AL, Uttenreuther-Fischer MM, Huang CS, et al. Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma. J Clin Oncol. 1998;16:2169–2180.
   PubMed Web of Science ®Google Scholar
• Shibuya H, Hamamura K, Hotta H, et al. Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3. Cancer Sci. 2012;103:1656–1664.
   PubMed Web of Science ®Google Scholar
• Poon VI, Roth M, Piperdi S, et al. Ganglioside GD2 expression is maintained upon recurrence in patients with osteosarcoma. Clin Sarcoma Res. 2015;5:4.
   PubMed Web of Science ®Google Scholar
• Roth M, Linkowski M, Tarim J, et al. Ganglioside GD2 as a therapeutic target for antibody-mediated therapy in patients with osteosarcoma. Cancer. 2014;120:548–554.
   PubMed Web of Science ®Google Scholar
• Liu B, Wu Y, Zhou Y, et al. Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells. PLoS One. 2014;9:e93576.
   PubMed Web of Science ®Google Scholar
• Hamanishi J, Mandai M, Matsumura N, et al. PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol. 2016;21:456–461.
   PubMed Web of Science ®Google Scholar
• Shen JK, Cote GM, Choy E, et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res. 2014;2:690–698.
   PubMed Web of Science ®Google Scholar
• Nowicki TS, Anderson JL, Federman N. Prospective immunotherapies in childhood sarcomas: PD1/PDL1 blockade in combination with tumor vaccines. Pediatr Res. 2016;79:371–377.
   PubMed Web of Science ®Google Scholar
• Tsukahara T, Emori M, Murata K, et al. The future of immunotherapy for sarcoma. Expert Opin Biol Ther. 2016;27:1–9.
   Google Scholar
• Mandai M, Hamanishi J, Abiko K, et al. Dual faces of IFNγ in cancer progression: a role of PD-L1 induction in the determination of pro- and antitumor immunity. Clin Cancer Res. 2016;22:2329–2334.
   PubMed Web of Science ®Google Scholar
• Festino L, Botti G, Lorigan P, et al. Cancer treatment with anti-PD-1/PD-L1 agents: is PD-L1 expression a biomarker for patient selection? Drugs. 2016;76:925–945.
   PubMed Web of Science ®Google Scholar
• Constantino J, Gomes C, Falcão A, et al. Antitumor dendritic cell-based vaccines: lessons from 20 years of clinical trials and future perspectives. Transl Res. 2016;168:74–95.
   PubMed Web of Science ®Google Scholar
• Chauvin C, Philippeau JM, Hémont C, et al. Killer dendritic cells link innate and adaptive immunity against established osteosarcoma in rats. Cancer Res. 2008;68:9433–9440109.
   PubMed Web of Science ®Google Scholar
• Krishnadas DK, Shusterman S, Bai F, et al. A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma. Cancer Immunol Immunother. 2015;64:1251–1260.
   PubMed Web of Science ®Google Scholar
• Himoudi N, Wallace R, Parsley KL, et al. Lack of T-cell responses following autologous tumour lysate pulsed dendritic cell vaccination, in patients with relapsed osteosarcoma. Clin Transl Oncol. 2012;14:271–279.
   PubMed Web of Science ®Google Scholar
• Allen B. Systemic targeted alpha radiotherapy for cancer. J Biomed Phys Eng. 2013;3:67–80.
   PubMedGoogle Scholar
• Anderson PM, Subbiah V, Rohren E. Bone-seeking radiopharmaceuticals as targeted agents of osteosarcoma: samarium-153-EDTMP and radium-223. Adv Exp Med Biol. 2014;804:291–304.
   PubMed Web of Science ®Google Scholar
• Henriksen G, Fisher DR, Roeske JC, et al. Targeting of osseous sites with alpha-emitting 223Ra: comparison with the beta-emitter 89Sr in mice. J Nucl Med. 2003;44:252–259.
   PubMed Web of Science ®Google Scholar
• Nilsson S, Larsen RH, Fosså SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005;11:4451–4459.
   PubMed Web of Science ®Google Scholar
• Sartor O, Coleman R, Nilsson S, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial. Lancet Oncol. 2014;15(7):738–746.
   PubMed Web of Science ®Google Scholar
• Mortensen DS, Perrin-Ninkovic SM, Shevlin G, et al. Optimization of a series of triazole containing mammalian target of rapamycin (mTOR) kinase inhibitors and the discovery of CC-115. J Med Chem. 2015;58:5599–5608.
   PubMed Web of Science ®Google Scholar
• Goodwin JF, Knidsen KE. Beyond DNA repair: DNA-PK function in cancer. Cancer Discov. 2014;4:1126–1139.
   PubMed Web of Science ®Google Scholar
• Mortensen DS, Fultz KE, Xu W, et al. Preclinical characterization of CC-115, a novel inhibitor of DNA-PK and mTOR kinase currently under clinical investigation. Eur J Cancer. 2014;50(Suppl 6):50.
   PubMed Web of Science ®Google Scholar
• Li X, Tian J, Bo Q, et al. Targeting DNA-PKcs increased anticancer drug sensitivity by suppressing DNA damage repair in osteosarcoma cell line MG63. Tumour Biol. 2015;36:9365–9372.
   PubMed Web of Science ®Google Scholar
• Sherr CJ, Beach D, Shapiro GI. Targeting CDK4 and CDK6: from discovery to therapy. Cancer Discov. 2016;6:353–367.
   PubMed Web of Science ®Google Scholar
• Zhou LT, Liu FY, Li Y, et al. Gpnmb/osteoactivin, an attractive target in cancer immunotherapy. Neoplasma. 2012;59:1–5.
   PubMed Web of Science ®Google Scholar
• Roth M, Barris DM, Piperdi S, et al. Targeting glycoprotein NMB with antibody-drug conjugate, glembatumumab vedotin, for the treatment of osteosarcoma. Pediatr Blood Cancer. 2016;63:32–38.
   PubMed Web of Science ®Google Scholar
• Bertrand N, Wu J, Xu X, et al. Cancer nanotechnology: the impact oive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev. 2014;66:2–25.
   PubMed Web of Science ®Google Scholar
• Wagner LM, Yin H, Eaves D, et al. Preclinical evaluation of nanoparticle albumin-bound paclitaxel for treatment of pediatric bone sarcoma. Pediatr Blood Cancer. 2014;61:2096–2098.
   PubMed Web of Science ®Google Scholar
• Kang MH, Wang J, Makena MR, et al. Activity of MM-398, nanoliposomal irinotecan (nal-IRI), in Ewing’s family tumor xenografts is associated with high exposure of tumor to drug and high SLFN11 expression. Clin Cancer Res. 2015;21:1139–1150.
   PubMed Web of Science ®Google Scholar
• McGovern SL, Mahajan A. Progress in radiotherapy for pediatric sarcomas. Curr Oncol Rep. 2012;14:320–326.
   PubMed Web of Science ®Google Scholar
• Matsunobu A, Imai R, Kamada T, et al. Impact of carbon ion radiotherapy for unresectable osteosarcoma of the trunk. Cancer. 2012;118:4555–4563.
   PubMed Web of Science ®Google Scholar
• Zhang W, Tanaka M, Sugimoto Y, et al. Carbon-ion radiotherapy of spinal osteosarcoma with long-term follow. Eur Spine J. 2016;25(Suppl 1):113–117.
   PubMed Web of Science ®Google Scholar
• Merchant MS, Wright M, Baird K, et al. Phase I clinical trial of ipilimumab in pediatric patients with advanced solid tumors. Clin Cancer Res. 2016;22:1364–1370.
   PubMed Web of Science ®Google Scholar
• Skoda J, Nunukova A, Loja T, et al. Cancer stem cell markers in pediatric sarcomas: Sox2 is associated with tumorigenicity in immunodeficient mice. Tumour Biol. 2016;37:9535–9548.
   PubMed Web of Science ®Google Scholar
• Yan GN, Lv YF, Guo QN. Advances in osteosarcoma stem cell research and opportunities for novel therapeutic targets. Cancer Lett. 2016;370:268–274.
   PubMed Web of Science ®Google Scholar
• Martins-Neves SR, Corver WE, Paiva-Oliveira DI, et al. Osteosarcoma stem cells have active Wnt/β-catenin and overexpress SOX2 and KLF4. J Cell Physiol. 2016;231:876–886.
   PubMed Web of Science ®Google Scholar
• Satelli A, Mitra A, Cutrera JJ, et al. Universal marker and detection tool for human sarcoma circulating tumor cells. Cancer Res. 2014;74:1645–150.
   PubMed Web of Science ®Google Scholar
• Chang L, Asatrian G, Dry SM, et al. Circulating tumor cells in sarcomas: a brief review. Med Oncol. 2015;32:430.
   PubMed Web of Science ®Google Scholar
• Tellez Gabriel M, Rodriguez Calleja L, Chalopin A, et al. Circulating tumor cells: a review of non-EpCAM-based approaches for cell enrichment and isolation. Clin Chem. 2016;62:571–581.
   PubMed Web of Science ®Google Scholar
• Bolognesi C, Forcato C, Buson G, et al. Digital sorting of pure cell populations enables unambiguous genetic analysis of heterogeneous formalin-fixed paraffin-embedded tumors by next generation sequencing. Sci Rep. 2016;6:20944.
   PubMed Web of Science ®Google Scholar